What it sells
Gene editing technology.
Business model breakdown
Buyer: who owns the budget?
UnverifiedR&D/trait-development leadership at crop developers and ag-biotech companies (site: 'a next-gen solution for crop developers').
Trigger: what makes them buy now?
Legacy trait development is slow and expensive with repeated breeding cycles; CRISPR only makes small edits.
Workflow: what inputs become what output?
CRISPR targets a genome site, TAHITI transposable elements insert large DNA cargo there.
Economics: what it saves and how it charges
UnverifiedLikely licensing or partnership revenue from the TAHITI platform.
Distribution: how it reaches customers
'Partner With Us' business development with crop developers.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-09-17 | Seed | — | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.